Shares of AcelRx Pharmaceuticals Inc. (NASDAQ:ACRX) were down 2.7% during trading on Tuesday . The stock traded as low as $3.55 and last traded at $3.57, with a volume of 302,963 shares changing hands. The stock had previously closed at $3.67.

Several analysts have commented on ACRX shares. RBC Capital Markets reaffirmed a “positive” rating and set a $6.00 price objective on shares of AcelRx Pharmaceuticals in a research note on Tuesday. Jefferies Group reissued a “buy” rating on shares of AcelRx Pharmaceuticals in a research note on Wednesday, August 10th. Cowen and Company reissued a “hold” rating on shares of AcelRx Pharmaceuticals in a research note on Friday, July 29th. Stifel Nicolaus downgraded AcelRx Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Friday, August 5th. Finally, HC Wainwright reissued a “buy” rating on shares of AcelRx Pharmaceuticals in a research note on Monday, August 1st. One analyst has rated the stock with a sell rating, three have assigned a hold rating and five have assigned a buy rating to the stock. The company currently has a consensus rating of “Hold” and a consensus price target of $7.30.

The firm’s 50-day moving average is $3.17 and its 200-day moving average is $3.34. The stock’s market capitalization is $161.76 million.

AcelRx Pharmaceuticals (NASDAQ:ACRX) last posted its quarterly earnings results on Thursday, July 28th. The specialty pharmaceutical company reported ($0.24) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.22) by $0.02. The company earned $4.53 million during the quarter, compared to analyst estimates of $2.17 million. On average, analysts predict that AcelRx Pharmaceuticals Inc. will post ($0.91) earnings per share for the current fiscal year.

AcelRx Pharmaceuticals, Inc is a pharmaceutical company focused on the development and commercialization of therapies for the treatment of moderate-to-severe acute pain. The Company operates through the segment, which includes development and commercialization of product candidates for the treatment of pain.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.